Population Pharmacokinetics, Safety and Tolerability of Extended-Release Bupropion and Its Three Metabolites in Chinese Healthy Volunteers

ConclusionsThis was the first pharmacokinetic study for bupropion XL and its active metabolites in the Chinese population. The AUC andCmax of bupropion XL and its three metabolites increased approximately in a dose-proportional manner with an increase from 150  mg to 300 mg. Adverse events were similar to those reported in studies outside China. A population pharmacokinetic model was developed for bupropion XL, with pharmacokinetics of bupropion adequately described by a two-compartment model with first-order absorption and linear elimination plus lag t ime.Trial Registration NumberNCT02698553
Source: European Journal of Drug Metabolism and Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research